Table 1 Baseline characteristics of participants at initial evaluation
From: Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease
|  | Total (n = 365) | Group A*(n = 278) | Group B†(n = 87) | p-value |
|---|---|---|---|---|
Male (%) | 183 (50.1%) | 122 (43.9%) | 61 (70.1%) | < 0.001 |
Age (yrs) | 43.5 ± 11.9 | 42.4 ± 11.3 | 47.1 ± 13.2 | 0.003 |
 18-39 | 159 (43.6%) | 128 (46.0%) | 31 (35.6%) |  |
 40-59 | 177 (48.5%) | 133 (47.8%) | 44 (50.6%) |  |
 ≥ 60 | 29 (7.9%) | 17 (6.1%) | 12 (13.8%) |  |
Follow up time (months) | 73.5 ± 43.4 | 76.2 ± 43.5 | 64.7 ± 42.1 | 0.031 |
Hypertension (%) | 257 (70.4%) | 186 (66.9%) | 71 (81.6%) | 0.004 |
Systolic BP (mmHg) | 136.4 ± 19.9 | 136.4 ± 20.3 | 136.3 ± 18.8 | 0.967 |
Diastolic BP (mmHg) | 85.6 ± 13.9 | 86.1 ± 14.2 | 83.6 ± 12.8 | 0.190 |
Urinary stone (%) | 96 (26.3%) | 71 (25.5%) | 25 (28.7%) | 0.556 |
sUA (mg/dL) | 5.51 ± 1.71 | 4.80 ± 1.11 | 7.76 ± 1.26 | < 0.001 |
sCr (mg/dL) | 1.17 ± 0.48 | 1.01 ± 0.23 | 1.67 ± 0.69 | < 0.001 |
eGFR (ml/min/1.73 m2) | 75.1 ± 24.1 | 81.6 ± 19.3 | 54.5 ± 26.3 | < 0.001 |
CKD stage | Â | Â | Â | < 0.001 |
 Stage 1 | 95 (26.0%) | 53 (19.1%) | 6 (6.9%) |  |
 Stage 2 | 184 (50.4%) | 189 (68.0%) | 28 (32.2%) |  |
 Stage 3 | 63 (17.3%) | 35 (12.6%) | 33 (37.9%) |  |
 Stage 4 | 23 (6.3%) | 1 (0.4%) | 20 (23.0%) |  |
Urine pH | 6.03 ± 0.73 | 6.13 ± 0.73 | 5.74 ± 0.66 | < 0.001 |
Dipstick albumin | Â | Â | Â | 0.017 |
 None to 1+ | 342 (93.7%) | 266 (95.7%) | 76 (87.4%) |  |
 > 1+ | 23 (6.3%) | 12 (4.3%) | 11 (12.6%) |  |
TKV (mL) | 1,524 ± 1,171 | 1,416 ± 1,050 | 1,963 ± 1,500 | 0.013 |
Losartan (%) | 58 (15.9%) | 50 (18.0%) | 8 (9.2%) | 0.025 |
Diuretic (%) | 36 (9.9%) | 27 (9.7%) | 9 (10.3%) | 0.863 |